Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of LX22001 in Healthy Subjects
NCT06561542Phase 1Recruiting
- Sponsor
- Shandong Luoxin Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of LX22001 in gastroesophageal reflux disease (GERD), Peptic ulcer disease (PUD), duodenal ulcer and 1 more (3 arms), sponsored by Shandong Luoxin Pharmaceutical. Primary endpoint: Number of Participants With Adverse Events. Started Aug 2024; status: recruiting.
02
Drugs
LX22001
03
Conditions
gastroesophageal reflux disease (GERD)Peptic ulcer disease (PUD)duodenal ulcerPeptic ulcer hemorrhage (PUB)
Beyond the preview
Go deeper on NCT06561542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561542.